CalciMedica annual r&d spending
2019
2020
2021
2022
2023
2024
2025
CalciMedica R&D Spending Growth & History (CALC)
CalciMedica's r&d spending was $15.2M for fiscal 2025.
View full CalciMedica company overviewCalciMedica annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $15.2M | $756,000 | +5.22% |
| 2024 | 2024-12-31 | $14.5M | −$1.4M | −8.71% |
| 2023 | 2023-12-31 | $15.9M | $7.5M | +89.93% |
| 2022 | 2022-12-31 | $8.3M | −$10.6M | −55.83% |
| 2021 | 2021-12-31 | $18.9M | −$2.1M | −9.82% |
| 2020 | 2020-12-31 | $21.0M | −$9.6M | −31.45% |
| 2019 | 2019-12-31 | $30.6M | — | — |
CalciMedica quarterly r&d spending
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.1M | −$1.9M | −48.12% |
| Q1 2026 | 2026-03-31 | $3.5M | −$739,000 | −17.50% |
| Q4 2025 | 2025-12-31 | $3.1M | −$724,000 | −18.90% |
| Q3 2025 | 2025-09-30 | $3.9M | $305,000 | +8.60% |
| Q2 2025 | 2025-06-30 | $4.1M | −$105,000 | −2.53% |
| Q1 2025 | 2025-03-31 | $4.2M | $1.3M | +43.48% |
| Q4 2024 | 2024-12-31 | $3.8M | $1.0M | +37.71% |
| Q3 2024 | 2024-09-30 | $3.5M | $774,000 | +27.92% |
| Q2 2024 | 2024-06-30 | $4.2M | $343,000 | +8.99% |
| Q1 2024 | 2024-03-31 | $2.9M | −$3.5M | −54.64% |
| Q4 2023 | 2023-12-31 | $2.8M | $860,000 | +44.75% |
| Q3 2023 | 2023-09-30 | $2.8M | $1.5M | +122.83% |
| Q2 2023 | 2023-06-30 | $3.8M | $1.6M | +68.84% |
| Q1 2023 | 2023-03-31 | $6.5M | $3.6M | +121.91% |
| Q4 2022 | 2022-12-31 | $1.9M | −$2.3M | −54.97% |
| Q3 2022 | 2022-09-30 | $1.2M | −$2.8M | −69.06% |
| Q2 2022 | 2022-06-30 | $2.3M | −$1.9M | −45.78% |
| Q1 2022 | 2022-03-31 | $2.9M | −$3.5M | −54.64% |
| Q4 2021 | 2021-12-31 | $4.3M | −$1.2M | −22.23% |
| Q3 2021 | 2021-09-30 | $4.0M | −$736,000 | −15.47% |
| Q2 2021 | 2021-06-30 | $4.2M | −$466,000 | −10.06% |
| Q1 2021 | 2021-03-31 | $6.4M | $363,000 | +5.97% |
| Q4 2020 | 2020-12-31 | $5.5M | — | — |
| Q3 2020 | 2020-09-30 | $4.8M | −$3.6M | −43.39% |
| Q2 2020 | 2020-06-30 | $4.6M | — | — |
| Q1 2020 | 2020-03-31 | $6.1M | — | — |
| Q3 2019 | 2019-09-30 | $8.4M | — | — |
CalciMedica r&d spending trends
Over the last five fiscal years, CalciMedica's r&d spending decreased from $21.0M to $15.2M, a change of −$5.7M. The latest reported quarter, Q2 2026, shows $2.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CalciMedica source filings ↗